20:52 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cyclerion's sGC stimulator praliciguat ameliorates NASH in rodents

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Rat and mouse studies suggest the systemic sGC stimulator praliciguat could help treat NASH. In liver samples from patients, levels of an sGC subunit were higher in fibrotic...
22:13 , Feb 22, 2019 |  BC Extra  |  Politics & Policy

China releases list of rare disease drugs with reduced VAT

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...
18:43 , Jan 18, 2019 |  BC Week In Review  |  Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...
13:04 , Jan 16, 2019 |  BC Extra  |  Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat: Final Phase IIIb data

Final data from 61 PAH patients who had an insufficient response to treatment with phosphodiesterase-5 (PDE-5) inhibitors alone or in combination with an endothelin receptor antagonist in the open-label, international Phase IIIb RESPITE trial showed...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat regulatory update

EMA’s CHMP recommended against the use of Adempas riociguat from Bayer to treat pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP). CHMP said the recommendation follows the early termination of the Phase II RISE-IIP trial...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat: Phase IIb discontinued

Bayer discontinued the double-blind, placebo-controlled, international Phase IIb RISE-IIP trial in 147 patients after the study’s IDMC observed that patients receiving Adempas were at a “possible increased risk for death and other serious adverse events”...
00:37 , May 13, 2016 |  BC Extra  |  Clinical News

Bayer halts Adempas trial on safety concerns

Bayer AG (Xetra:BAYN) said it stopped the 147-patient Phase IIb RISE-IIP study of Adempas riociguat to treat pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP) after the study's independent DMC "observed that patients receiving riociguat...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Soluble guanylate cyclase (sGC)

Renal disease INDICATION: Diabetic nephropathy Rat studies suggest activating sGC could help treat diabetic nephropathy. In a rat model of diabetic nephropathy, oral 0.3, 1, 3 and 10 mg/kg doses of an undisclosed sGC activator...